Ponatinib - Wikipedia
Ponatinib, sold under the brand name Iclusig, is a medication used for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia. [4] It was developed by Ariad Pharmaceuticals .
Ponatinib (oral route) - Mayo Clinic
Ponatinib is an antineoplastic (cancer) medicine. It interferes with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal cells may also be affected by ponatinib, other side effects can occur.
ICLUSIG® (ponatinib) Treatment in CML and Ph+ ALL
What is the most important information I should know about ICLUSIG® (ponatinib)? ICLUSIG can cause serious side effects, including: Blood clots or blockage in your blood vessels (arteries and veins).
Ponatinib Information for Patients - Drugs.com
2023年8月23日 · Ponatinibis used in adults to treat a type of blood cancer called chronic myeloid leukemia (CML), or Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Ponatinib is usually given after other similar medications have been tried without success.
Iclusig® (ponatinib) is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior...
Ponatinib Side Effects: Common, Severe, Long Term - Drugs.com
2023年9月27日 · Learn about the side effects of ponatinib, from common to rare, for consumers and healthcare professionals.
Ponatinib Tablet - Uses, Side Effects, and More - WebMD
Ponatinib is used to treat certain types of blood cancer (chronic myelogenous leukemia -CML, acute lymphoblastic leukemia -ALL). It works by slowing or stopping the growth of cancer cells. It...
Ponatinib: MedlinePlus Drug Information
Ponatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
Ponatinib: Uses, Interactions, Mechanism of Action - DrugBank …
Ponatinib is a kinase inhibitor used to treat patients with various types of chronic myeloid leukemia (CML). Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on …
Ponatinib - Macmillan Cancer Support
Ponatinib is a type of targeted therapy drug called a cancer growth inhibitor. Ponatinib is used to treat some types of leukaemia . It may sometimes be used to treat other cancers.